Analyst Ratings for Madrigal Pharmaceuticals (MDGL)
MDGL Rating Summary
MDGL Price Target Summary
- Highest: $565.00 (Goldman Sachs)
- Lowest: $270.00 (B.Riley)
- Average: $400.27
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$400.27 (+80.1%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 86%
Avg. $ Target:
$400.27 (+80.1%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 86%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/15/2024 | B.Riley | Mayank Mamtani | Upgrade | Neutral (Sell) |
270.00 (155.00) |
272.98 (222.26) |
-18.58% | Details |
| 3/6/2024 | Citi » Updated 3/18/2024 |
David Lebowitz | New Coverage | Buy (N/A) |
389.00 (N/A) |
246.56 (222.26) |
-9.86% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
